|
GB8712540D0
(en)
|
1987-05-28 |
1987-07-01 |
Ucb Sa |
Expression of human proapolipoprotein a-i
|
|
US5220043A
(en)
|
1991-03-21 |
1993-06-15 |
Ohio University |
Synthesis of D-erythro-sphingomyelins
|
|
SE9103701D0
(sv)
|
1991-12-13 |
1991-12-13 |
Kabi Pharmacia Ab |
Apolipoprotein
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
SE9203753D0
(sv)
|
1992-12-11 |
1992-12-11 |
Kabi Pharmacia Ab |
Expression system for producing apolipoprotein ai-m
|
|
FR2704556B1
(fr)
|
1993-04-30 |
1995-07-13 |
Rhone Poulenc Rorer Sa |
Virus recombinants et leur utilisation en thérapie génique.
|
|
CA2185450A1
(en)
|
1994-03-22 |
1995-09-28 |
Patrick Tso |
Eating suppressant peptides
|
|
US5932536A
(en)
|
1994-06-14 |
1999-08-03 |
The Rockefeller University |
Compositions for neutralization of lipopolysaccharides
|
|
SE9500778D0
(sv)
|
1995-03-03 |
1995-03-03 |
Pharmacia Ab |
Process for producing a protein
|
|
US5648387A
(en)
|
1995-03-24 |
1997-07-15 |
Warner-Lambert Company |
Carboxyalkylethers, formulations, and treatment of vascular diseases
|
|
US6258596B1
(en)
|
1995-05-22 |
2001-07-10 |
Aventis Pharmaceuticals Products Inc. |
Variants of apolipoprotein A-I
|
|
GB9526733D0
(en)
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
|
SE9603068D0
(sv)
|
1996-08-23 |
1996-08-23 |
Pharmacia & Upjohn Ab |
Process for purifying a protein
|
|
SE9603304D0
(sv)
|
1996-09-11 |
1996-09-11 |
Pharmacia & Upjohn Ab |
Process for purifying a compound
|
|
SE9603303D0
(sv)
|
1996-09-11 |
1996-09-11 |
Pharmacia & Upjohn Ab |
Process for purifying a protein
|
|
US6306433B1
(en)
|
1997-08-12 |
2001-10-23 |
Pharmacia Ab |
Method of preparing pharmaceutical compositions
|
|
US6037323A
(en)
|
1997-09-29 |
2000-03-14 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6518412B1
(en)
|
1997-09-29 |
2003-02-11 |
Jean-Louis Dasseux |
Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6046166A
(en)
|
1997-09-29 |
2000-04-04 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6004925A
(en)
|
1997-09-29 |
1999-12-21 |
J. L. Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6287590B1
(en)
|
1997-10-02 |
2001-09-11 |
Esperion Therapeutics, Inc. |
Peptide/lipid complex formation by co-lyophilization
|
|
CA2356704A1
(en)
|
1998-12-30 |
2000-07-13 |
Folke Tjerneld |
Separation method utilizing liquid-liquid partition
|
|
US6410802B1
(en)
|
1999-04-01 |
2002-06-25 |
Esperion Therapeutics, Inc. |
Methods for synthesizing ether compounds and intermediates therefor
|
|
GB9919713D0
(en)
|
1999-08-19 |
1999-10-20 |
Queen Mary & Westfield College |
New medical use of high density lipoprotein
|
|
US6946134B1
(en)
|
2000-04-12 |
2005-09-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
EP2213743A1
(en)
|
2000-04-12 |
2010-08-04 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
DE60117781T2
(de)
|
2000-04-21 |
2006-11-23 |
Amgen Inc., Thousand Oaks |
Peptidderivate des apolipoproteins-a1/aii
|
|
US7723303B2
(en)
|
2000-08-24 |
2010-05-25 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
|
US7144862B2
(en)
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
US7166578B2
(en)
|
2000-08-24 |
2007-01-23 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
|
US7199102B2
(en)
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
US7148197B2
(en)
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
|
US6664230B1
(en)
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
CN101426763A
(zh)
|
2000-10-11 |
2009-05-06 |
埃斯佩里安医疗公司 |
用于胆固醇治疗和相关应用的硫化物和二硫化物化合物和组合物
|
|
CA2425311C
(en)
|
2000-10-11 |
2011-06-14 |
Esperion Therapeutics, Inc. |
Ketone compounds and compositions for cholesterol management and related uses
|
|
CN1894195A
(zh)
|
2000-10-11 |
2007-01-10 |
埃斯佩里安医疗公司 |
用于控制胆固醇以及相关用途的醚化合物以及组合物
|
|
JP2004531459A
(ja)
|
2000-10-11 |
2004-10-14 |
エスペリオン セラピューティクス，インコーポレイテッド |
コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用
|
|
US7304093B2
(en)
|
2000-10-11 |
2007-12-04 |
Esperion Therapeutics, Inc. |
Ketone compounds and compositions for cholesterol management and related uses
|
|
BR0115257A
(pt)
|
2000-11-10 |
2003-08-12 |
Proteopharma Aps |
Análogos de apolipoproteìna
|
|
US7507413B2
(en)
|
2001-04-12 |
2009-03-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7217785B2
(en)
|
2001-05-09 |
2007-05-15 |
The Regents Of The University Of California |
Cysteine-containing peptides having antioxidant properties
|
|
US7033500B2
(en)
|
2001-06-25 |
2006-04-25 |
Lipid Sciences, Inc. |
Systems and methods using multiple solvents for the removal of lipids from fluids
|
|
US20060060520A1
(en)
|
2001-06-25 |
2006-03-23 |
Bomberger David C |
Systems and methods using a solvent for the removal of lipids from fluids
|
|
US6991727B2
(en)
|
2001-06-25 |
2006-01-31 |
Lipid Sciences, Inc. |
Hollow fiber contactor systems for removal of lipids from fluids
|
|
DE60226881D1
(de)
|
2001-08-20 |
2008-07-10 |
Zlb Bioplasma Ag |
High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen
|
|
AUPR798901A0
(en)
|
2001-09-28 |
2001-10-25 |
Medvet Science Pty. Ltd. |
Spheroidal hdl particles with a defined phospholipid composition
|
|
PL372925A1
(en)
|
2001-09-28 |
2005-08-08 |
Esperion Therapeutics Inc. |
Prevention and treatment of restenosis by local administration of drug
|
|
WO2005003296A2
(en)
|
2003-01-22 |
2005-01-13 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
AU2002364586A1
(en)
|
2001-12-21 |
2003-07-30 |
Delta Biotechnology Limited |
Albumin fusion proteins
|
|
US7223726B2
(en)
|
2002-01-14 |
2007-05-29 |
The Regents Of The University Of California |
Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
|
|
US6930085B2
(en)
|
2002-04-05 |
2005-08-16 |
The Regents Of The University Of California |
G-type peptides to ameliorate atherosclerosis
|
|
JP2006507223A
(ja)
|
2002-05-17 |
2006-03-02 |
エスペリオン セラピューティクス，インコーポレイテッド |
脂質代謝異常疾患の治療方法
|
|
EP1545576A2
(en)
|
2002-07-30 |
2005-06-29 |
Esperion Therapeutics Inc. |
Methods of using non-human animal apoliprotein a-i protein
|
|
ES2625429T3
(es)
|
2003-01-23 |
2017-07-19 |
Esperion Therapeutics Inc. |
Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes
|
|
US7393826B2
(en)
|
2003-07-03 |
2008-07-01 |
Lipid Sciences, Inc. |
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
|
|
CA2531227A1
(en)
|
2003-07-03 |
2005-02-10 |
Lipid Sciences Inc. |
Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
|
|
ATE428411T1
(de)
|
2003-11-07 |
2009-05-15 |
Jj Pharma Inc |
Hdl-verstärkende kombinationstherapie-komplexe
|
|
TW200526778A
(en)
|
2003-11-14 |
2005-08-16 |
Sembiosys Genetics Inc |
Methods for the production of apolipoproteins in transgenic plants
|
|
ES2381551T3
(es)
|
2003-12-05 |
2012-05-29 |
The Cleveland Clinic Foundation |
Marcadores de riesgo para enfermedad cardiovascular
|
|
CA2549529A1
(en)
|
2003-12-15 |
2005-06-30 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
|
JP2007525408A
(ja)
|
2003-12-24 |
2007-09-06 |
エスペリオン セラピューティクス，インコーポレイテッド |
コレステロール管理および関連使用のためのケトン化合物および組成物
|
|
KR100560102B1
(ko)
|
2004-06-25 |
2006-03-13 |
한국생명공학연구원 |
프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
|
|
US7378396B2
(en)
|
2004-08-11 |
2008-05-27 |
The Cleveland Clinic Foundation |
Therapeutic agents and methods for cardiovascular disease
|
|
AU2005295640B2
(en)
|
2004-10-15 |
2011-07-28 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Multi-domain amphipathic helical peptides and methods of their use
|
|
US8206750B2
(en)
|
2005-03-24 |
2012-06-26 |
Cerenis Therapeutics Holding S.A. |
Charged lipoprotein complexes and their uses
|
|
ES2402823T3
(es)
|
2006-06-01 |
2013-05-09 |
Institut De Cardiologie De Montreal |
Compuesto para uso en el tratamiento de estenosis valvular
|
|
AU2007284801A1
(en)
|
2006-08-08 |
2008-02-21 |
The Regents Of The University Of Californina |
Salicylanilides enhance oral delivery of therapeutic peptides
|
|
US8541236B2
(en)
|
2006-12-08 |
2013-09-24 |
University Of Washington |
Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
|
|
PT2118074E
(pt)
|
2007-02-01 |
2014-03-20 |
Resverlogix Corp |
Compostos para a prevenção e tratamento de doenças cardiovasculares
|
|
US7956035B2
(en)
|
2007-03-01 |
2011-06-07 |
Csl Limited |
Treatment of endothelial dysfunction in diabetic patients
|
|
US7749315B2
(en)
|
2007-04-04 |
2010-07-06 |
Xerox Corporation |
Phase change inks containing colorant compounds
|
|
CA2694854C
(en)
|
2007-08-17 |
2016-09-27 |
Csl Behring Gmbh |
Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
|
|
WO2009032702A2
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
|
US8044021B2
(en)
|
2007-09-20 |
2011-10-25 |
Abbott Cardiovascular Systems Inc. |
Sustained release of apo A-I mimetic peptides and methods of treatment
|
|
US7985728B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US7985727B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Apo A-I mimetic peptides and methods of treatment
|
|
US8101565B2
(en)
|
2007-09-20 |
2012-01-24 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
WO2009050275A1
(en)
|
2007-10-19 |
2009-04-23 |
Pronota N.V. |
A protease-sensitive site in apolipoprotein a1, therapeutic and diagnostic implications
|
|
WO2009055538A1
(en)
|
2007-10-23 |
2009-04-30 |
The Cleveland Clinic Foundation |
Oxidant resistant apolipoprotein a-1 and mimetic peptides
|
|
WO2009155366A2
(en)
|
2008-06-18 |
2009-12-23 |
The Regents Of The University Of California |
Improved peptide mediators of cholesterol efflux
|
|
JP5719783B2
(ja)
|
2009-02-16 |
2015-05-20 |
セレニス セラピューティクス ホールディング エスアー |
アポリポタンパクａ−ｉ模倣物
|
|
KR101766408B1
(ko)
|
2009-06-10 |
2017-08-10 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
|
WO2011079214A1
(en)
*
|
2009-12-23 |
2011-06-30 |
Artery Therapeutics, Inc., |
Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases
|
|
ES2617977T3
(es)
|
2010-06-30 |
2017-06-20 |
Csl Limited |
Una formulación de lipoproteína de alta densidad reconstituida y método de producción de la misma
|
|
HUE042314T2
(hu)
|
2011-02-07 |
2019-06-28 |
Cerenis Therapeutics Holding Sa |
Lipoprotein komplexek és azok gyártása és alkalmazásai
|